Press
Recursion in the News
stdClass Object
(
[limit] => 200
[order_by] => publish_date
[order] => desc
[post_types] => Array
(
[0] => press-article
[1] => press-release
)
[template] => press_release
[filter_by] =>
[acf_field] =>
[tax] => Array
(
)
[acf] =>
)
- All
- 2014
- 2015
- 2016
- 2017
01.31.20
Silicon Slopes: Chris Gibson, Co-Founder & CEO, Recursion
Nasdaq chats with Chris Gibson, PhD, Co-Founder & CEO of Recursion, at Silicon Slopes.
12.23.19
In good companies
Co-Founder and CEO Chris Gibson, PhD, shares news about our strategy to spin-out our first subsidiary to shepherd our lead clinical-stage asset for Neurofibromatosis Type 2 (NF2).
11.21.19
Recursion Building Onsite Childcare Facility to Support Working Parents
High-tech biopharma company partnering with childcare leader, Bright Horizons, to ensure working parents have the support they need to achieve their family and career ambitions
11.09.19
Gormley’s Take: Biotech and Tech VCs Have Different Views on AI-Based Drug Discovery
Two recent commentaries by biotechnology industry insiders highlighted a divide among venture capitalists: those who see artificial intelligence powering a revolution in drug discovery, and those who don’t.
10.21.19
Recursion Announces Winners of RxRx1 Biology Machine Learning Competition
More than 860 teams participated in the competition with the goal of developing machine learning methods that identify representations of biology from Recursion’s first-ever open-source dataset
09.20.19
The billion-dollar race to change how drugs are made
Alphabet’s AI lab DeepMind is proving that artificial intelligence can be game-changing for drug discovery. Could savvy upstarts upend Big Pharma?
09.13.19
Artificial intelligence takes on big pharma
Recursion focuses on fixing some of the costly inefficiencies plaguing the healthcare industry by using artificial intelligence (AI) technology to dramatically alter the entire drug discovery process.
08.21.19
Dr. Imran S. Haque, Biology Machine Learning Expert, joins Recursion as VP of Data Science
Big data innovator well known for his high standards and rigorous approach to medical machine learning joins Recursion following senior roles at Freenome and Counsyl
08.16.19
Machine learning brings cell imaging promises into focus
Recursion is at the forefront of combining cell imaging and machine learning to search for drugs.
08.04.19
Is Utah poised to become the best place for women in tech?
Senior Director of Data Science Product Lina Nilsson pens an op-ed on how Utah could become more inclusive than the high-tech hubs that came before it.
07.31.19
Recursion Appoints Heather Kirkby as Chief People Officer
Former VP of Talent at Intuit relocates from San Francisco to Salt Lake City to uplevel Recursion’s commitment to creating an inclusive and progressive workplace
07.25.19
The subtle art of really big data: Recursion Pharma maps the body
CEO Chris Gibson and CTO/CPO Mason Victors talk with ZDNet about what makes our image-based machine learning approach so unique.
07.15.19
Recursion Pharmaceuticals raises $121m to map how disease affects cells
Financial Times interviews CEO Chris Gibson and investors at Lux Capital and Baillie Gifford to learn more about our Series C financing.
07.15.19
AI Drug Hunters Could Give Big Pharma a Run for Its Money
Recursion and CEO/co-founder Chris Gibson are featured in Bloomberg's story on how pharma is using AI to conduct drug development.
07.15.19
Recursion Pharmaceuticals Secures $121 Million in Series C Financing
Led by Baillie Gifford, the new round will support the advancement of Recursion’s machine learning-enabled platform and first two clinical-stage programs
06.20.19
Recursion Appoints Dr. Sharath Hegde as its Chief Scientific Officer
Dr. Hegde brings decades of experience discovering and developing new medicines to clinical-stage biotech at the forefront of applying AI to drug discovery
05.06.19
Recursion Releases Open-Source Data from Largest Ever Dataset of Biological Images, Inviting Data Science Community to Develop New and Improved Machine Learning Algorithms for the Life Sciences Industry
Clinical-stage biotech offering unique access to cell biology images to drive more effective AI methods in drug discovery and development
03.01.19
Recursion and Center for Technology & Venture Commercialization to Jointly Launch Incubator
An incubator measuring 14,500-square-feet, including 5,000 square feet of wet laboratory space, will soon be available
02.20.19
Recursion Named as one of World’s Most Innovative Companies
Fast Company’s Annual List of the World’s Most Innovative Companies Honors Recursion with a Coveted Ranking
02.19.19
From Augmenting To Disrupting: How AI Will Tackle Complex Diseases
With modern computing, we are finding treatments for a range of diseases
01.07.19
Options Exercised by Takeda and AI Collaboration Extended
From collaboration to licensing options in less than 18 months
01.04.19
Recursion Signs Global Licensing Agreement
Contract signed with the Ohio State Innovation Foundation to Develop REC-2282 to Treat Neurofibromatosis Type 2
11.08.18
Recursion Secures $1.6M NIH Phase 2 SBIR Grant to Identify Therapeutic Candidates for Senescence, a Key Age-Related Disease Process
Recursion Secures $1.6M NIH Phase 2 SBIR Grant for Senescence
11.05.18
Recursion Named One of Utah’s 2018 Top Workplaces by The Salt Lake Tribune
07.10.18
AI/ML-based drugmaker gets FDA green light for Phase I study
Recursion plans to start study of machine learning-discovered drug REC-994 later this year, CEO says.
07.10.18
Veteran Biopharma Operations Leader Tina M. Larson to Join Recursion as Chief Operating Officer
Recursion adds industry leader in developing and manufacturing biopharmaceuticals
07.10.18
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Up to 1.5 million individuals in the United States with CCM may be impacted
06.05.18
Square 1 Bank Announces Credit Facility to Recursion Pharmaceuticals
Square 1 Bank announced that it has provided a $20.5 million credit facility to Recursion Pharmaceuticals
05.15.18
Medicinal Chemistry Leaders Drs. Phil Carpino and Mike Genin Form New Chemistry Team at Recursion Pharmaceuticals
Former Pfizer and Eli Lilly chemists join Recursion
05.07.18
Recursion Pharmaceuticals Receives Grant to Leverage AI-Enabled Discovery Platform in Infectious Disease
The grant will accelerate the discovery of treatments for malaria
05.01.18
Pharmaceutical Business Development Leader Dr. Kevin Lynch Joins Recursion as Chief Business Officer
Dr. Lynch joins Recursion during a rapid expansion in the company’s drug discovery efforts
04.23.18
Recursion CEO Chris Gibson one of Endpoints' "Under-40s"
The next generation of biopharma executives shares views on the future of the industry
04.18.18
Nathan Hatfield recognized as Corporate Counsel of the Year
Nathan joins the 2018 Corporate Counsel Award honorees - exceptional attorneys who are invaluable to their companies
02.22.18
Recursion featured in Rock Health's AI/ML in Healthcare Report
Recursion is profiled in Rock Health's whitepaper, "Demystifying AI and Machine Learning in Healthcare."
02.21.18
Recursion featured in BioUtah's 2018 Utah Life Sciences Report
Recursion is proud to contribute to the booming life sciences ecosystem in Utah
01.17.18
Recursion recognized on Women Tech Council 2018 Shatter List
Recursion is among 44 companies recognized for their efforts to shatter the glass ceiling
12.22.17
Recursion moving to new HQ in Spring 2018
Local biotech firm scores former Dick's Sporting Goods space
12.13.17
Recursion featured in CB Insights AI 100
Recursion is named as one of eight healthcare startups redefining the industry
12.11.17
Recursion named one of Fierce MedTech's 2017 Fierce 15
Recursion's use of artificial intelligence to discover 100 treatments by 2025 profiled by Fierce MedTech
11.30.17
Recursion announces its upcoming move to The Gateway
Vestar is adding Recursion to The Gateway’s mixed-use lifestyle and entertainment district in Salt Lake City’s western downtown area.
10.17.17
Dr. Martin Brenner Joins Recursion to Accelerate an Ambitious Plan to Industrialize Drug Discovery
The Industry Veteran Drug Hunter Brings more than a Decade of Experience to Recursion as Chief Scientific Officer
10.07.17
Recursion Pharma Gets Second Round This Year
$60 million Series B backs quest to find new drug targets
10.04.17
Recursion bags $60M for AI-enabled drug discovery push
Salt Lake City, Utah-based Recursion is built upon an AI-powered approach to phenotypic screening and other aspects of the drug discovery process.
10.03.17
Drug discovery startup Recursion raises $60 million in Series B from Data Collective
Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC).
10.03.17
Recursion Pharmaceuticals Raises $60 Million to Industrialize Drug Discovery using Artificial Intelligence
The over-subscribed round brings the company’s total capital raised to more than $80 million.
10.02.17
Recursion Pharmaceuticals Announces Research Collaboration with Takeda to Rapidly Build a Rare Disease Pipeline
Collaboration to leverage Recursion's AI-augmented phenotypic discovery platform, and Takeda's TAK-celerator™ program and chemical libraries.
10.01.17
Repurposing Recursion
Over the next 18 months, Recursion plans to pursue novel drug discovery internally and through ongoing and additional partnerships.
08.29.17
Machine Vision Helps Spot New Drug Treatments
A startup uses algorithms that understand the anatomy of cells to discover new uses for existing drugs.
08.17.17
How a start-up has found a dozen treatments for rare diseases using robots
Cerebral cavernous malformation isn't the kind of disease the average person is familiar with. But for the 0.5 percent of the population afflicted with the genetic affliction — which causes blood vessels in the brain to grow irregularly — every day can be terrifying.
08.10.17
10 AI Health Care Companies to Follow in 2017
The medical field is going through an evolution — and artificial intelligence is powering its push.
07.12.17
Yolanda Chong named as a finalist for the Women Tech Awards
Dr. Chong is driving innovation in drug discovery at Recursion Pharmaceuticals
06.28.17
Dr. Chand Sishta to lead regulatory affairs for Recursion Pharmaceuticals
Former Bristol-Myers Squibb scientist and regulatory affairs expert joins Recursion
06.26.17
KSL-TV feature story: Recursion Pharmaceuticals
Utah startup on the fast track to finding drug therapies for rare diseases
06.19.17
Blake Borgeson: CXO of the Year
Utah Business magazine selects C-level executives who are at the top of their respective fields. Congratulations to Blake Borgeson, Co-founder & Chief Technology Officer at Recursion Pharmaceuticals – he has been selected as one of the 2017 CXO of the Year honorees.
06.01.17
Recursion Featured on The Enterprisers Project
A bold machine learning project: Cure 100 diseases in 10 years
05.29.17
Recursion Featured on Deseret News
Utah company merging technology, biology to treat diseases
05.24.17
August Allen Named one of the 2017 PM360 Elite 100
PM360, the premier information resource for marketing decision makers in the pharmaceutical and medical device sectors, has named August Allen, Automation Scientist at Recursion Pharmaceuticals as one of the 2017 PM360 ELITE 100.
04.21.17
Recursion Captures Utah Innovation Award
Recursion Pharmaceuticals Captures Utah Innovation Award in the Life Science - BioTech Category
04.21.17
Yoshua Bengio joins Recursion Pharmaceuticals' Scientific & Technical Advisory Board
Deep Learning Luminary Yoshua Bengio Joins Recursion Pharmaceuticals as Key Advisor
04.19.17
Local firms ask Sen. Mike Lee to support grant funding for biotech
Finding cures and treatments for diseases is an expensive proposition that is often taken on by small, innovative companies in the biosciences industry being funded in part by government grants from the National Institutes of Health.
04.18.17
Dr. Yolanda Chong Joins Recursion Pharmaceuticals to Advance Discovery Platform
Former Johnson & Johnson scientist will expand Recursion's drug discovery capabilities
03.25.17
Top 50 MedTech Startups to Watch in 2017
Recursion Pharmaceuticals listed at #18
03.24.17
Recursion Pharmaceuticals is the newest member of the world’s most prominent rare disease consortium, IRDiRC
Recursion Pharmaceuticals has recently joined the International Rare Diseases Research Consortium (IRDiRC), as their newest member, to further advance their common goal
02.21.17
Old drugs, new uses
Most drugs that pharmaceutical companies begin developing never make it to market. A Utah-based startup reckons it can find new uses for abandoned drugs, with the help of image-recognition software. It could be a boon for the treatment of rare diseases
02.07.17
Square 1 Bank Announces Credit Facility to Recursion Pharmaceuticals
Square 1 Bank, a division of Pacific Western Bank, today announced that it has provided a $4 million credit facility to new client Recursion Pharmaceuticals, Inc., a leading pharmaceutical discovery company.
02.01.17
Three Tech Innovations That Could Save Your Life In 2017
Recursion Pharmaceuticals is working to potentially cut in half the development-to-market time for numerous drugs simultaneously which could ultimately impact the way patients are treated.
01.31.17
Top Artificial Intelligence Companies in Healthcare to Keep an Eye On
Speeding up the process of drug development and making it more cost-effective through AI technologies would have an enormous effect on today’s healthcare.
12.21.16
Recursion Receives Industry Awards for Drug Discovery Platform
Computationally intelligent drug discovery platform receives two Fierce Innovation awards for Biotech Innovation and Best New Product
11.22.16
Recursion Raises Additional Funding, Bringing Total Series A to $15.05M for Drug Discovery
The additional funding came from several high impact individual investors
11.14.16
Recursion Pharmaceuticals Selects Anaconda to Create Next-Gen Drug Discovery Platform
Bokeh on Anaconda makes it easy for biologists to identify genetic disease markers and assess drug efficacy when visualizing cell data, allowing for faster time-to-value for pharmaceutical companies.
10.25.16
Recursion Pharmaceuticals Announces John Pereira, MBA as Chief Operating Officer
Former COO of Experticity and VP of AncestryDNA, brings a wealth of experience in business management, operations and technology strategy to Recursion’s rapidly growing business.
10.04.16
Sanofi-partnered Recursion raises $13M for tech-enabled R&D drive
The idea is to pull in phenotypic data from cellular images, build disease models and then feed in the effects of potential drug candidates to discover which compounds could treat a particular condition.
10.03.16
Recursion Pharmaceuticals Raises $13M To Discover New Drugs Using Artificial Intelligence
Funding will be used to scale and expand Recursion’s groundbreaking platform, accelerating drug discovery to an unprecedented pace
09.13.16
Recursion Pharmaceuticals Receives Fast-Track SBIR Grant to Study Age-Related Disease
The award will support the application of Recursion’s advanced drug screening platform to finding treatments for chronic diseases of aging.
04.25.16
Recursion Pharmaceuticals Announces Research Agreement With Sanofi Genzyme
Recursion to deploy its drug repurposing platform identify new uses for Sanofi’s clinical stage molecules across dozens of genetic diseases.
02.25.16
Recursion Pharmaceuticals Supports White House Precision Medicine Initiative
Recursion Pharmaceuticals today announced that it is part of a group of nationally recognized private and public institutions making commitments as part of President Obama's Precision Medicine Initiative to rapidly find new treatments for ultra-rare genetic diseases.
12.08.15
Recursion Pharmaceuticals Receives $2.6 Million in Follow-on Seed Funding
Funding will be used to accelerate and scale the company’s proprietary drug discovery platform.
12.01.15
Keeping Pace: Who is driving drug discovery and where are we headed
For all the miraculous breakthroughs of medicine, the sober reality is that it’s never enough.
10.05.15
Recursion receives Orphan Drug Designation from the U.S. Food and Drug Administration for the use of Tempol in Cerebral Cavernous Malformation
Cerebral Cavernous Malformation is present in up to 1.5 million individuals in the United States.
02.28.15
Utah company gets NIH grant to help with repurposing drugs for rare diseases
A company started by a student who dropped out of the University of Utah School of Medicine to find cures for rare diseases has been awarded a $1.46 million federal grant.
02.25.15
Recursion Pharmaceuticals Wins $1.5M NIH Grant for Rare Disease Drug Discovery
The award will support the further development of Recursion’s Drug Screening Platform for hundreds of rare genetic diseases.
01.15.15
Five Biotech Startups to Watch in 2015
More money is being funneled into science based startups, especially fledgling companies in the biotech sector.
01.13.15
Five Biotech Startups to Watch in 2015
Recursion Pharmaceuticals is named as one of the innovative up and comers to watch.
12.08.14
University of Utah spin-off to speed discovery of orphan drugs
Develop 100 drugs in 10 years. That’s the ambitious goal set by a group of scientists and engineers at the University of Utah, founders of Recursion Pharmaceuticals, a start-up company that is able to quickly and affordably identify unexpected ways a drug could be used by testing it on diseased cells.
10.31.14
Recursion Pharmaceuticals Announces Robert Lollini as the Second Member of Business Advisory Panel
Lollini is a distinguished leader in the life sciences, having served as President and Chief Executive Officer of IOMED, Inc. and Myrexis, Inc.
06.04.14
Recursion Pharmaceuticals Announces Dr. H. Perry Fell as the First Member of Business Advisory Panel
H. Perry Fell, MBA, Ph.D. is a distinguished scientist and leader who most prominently co-founded Seattle Genetics (NASDAQ: SGEN) and served as its CEO from start-up through IPO.
04.08.14
Recursion Pharmaceuticals Announces Formation of its Scientific and Technical Advisory Board
These experts, along with several others to be announced at a later date, will advise Recursion Pharmaceuticals on a wide range of topics including scientific strategy, new technology, clinical impacts, and drug development.
